These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 38791284)

  • 21. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Lampson BL; Brown JR
    Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
    Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
    Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
    Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BTK inhibitors: past, present, and future.
    Cool A; Nong T; Montoya S; Taylor J
    Trends Pharmacol Sci; 2024 Aug; 45(8):691-707. PubMed ID: 39025681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
    Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
    Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of
    Quinquenel A; Fornecker LM; Letestu R; Ysebaert L; Fleury C; Lazarian G; Dilhuydy MS; Nollet D; Guieze R; Feugier P; Roos-Weil D; Willems L; Michallet AS; Delmer A; Hormigos K; Levy V; Cymbalista F; Baran-Marszak F;
    Blood; 2019 Aug; 134(7):641-644. PubMed ID: 31243043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
    Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK
    Curr Med Chem; 2024; 31(30):4757-4762. PubMed ID: 37818564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Wolska-Washer A; Robak P; Witkowska M; Robak T
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 40. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
    Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.